384 related articles for article (PubMed ID: 30001655)
21. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH
Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330
[TBL] [Abstract][Full Text] [Related]
22. [Clinical practice guideline for ANCA-associated vasculitis with renal involvement].
Vazquez V; Fayad A; González G; Smuclir Quevedo A; Robaina Sindín J;
Medicina (B Aires); 2015; 75 Suppl 1():1-38. PubMed ID: 26738202
[TBL] [Abstract][Full Text] [Related]
23. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
24. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
27. [ANCA-associated vasculitides : State of the art].
Hellmich B
Z Rheumatol; 2019 Aug; 78(6):518-528. PubMed ID: 31028473
[TBL] [Abstract][Full Text] [Related]
28. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
[TBL] [Abstract][Full Text] [Related]
29. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
30. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
31. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis.
Schirmer JH; Sanchez-Alamo B; Hellmich B; Jayne D; Monti S; Luqmani RA; Tomasson G
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37479496
[TBL] [Abstract][Full Text] [Related]
32. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
[TBL] [Abstract][Full Text] [Related]
33. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?
Alba MA; Flores-Suárez LF
Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570
[TBL] [Abstract][Full Text] [Related]
34. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.
Zeng L; Walsh M; Guyatt GH; Siemieniuk RAC; Collister D; Booth M; Brown P; Farrar L; Farrar M; Firth T; Fussner LA; Kilian K; Little MA; Mavrakanas TA; Mustafa RA; Piram M; Stamp LK; Xiao Y; Lytvyn L; Agoritsas T; Vandvik PO; Mahr A
BMJ; 2022 Feb; 376():e064597. PubMed ID: 35217581
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
36. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic strategies in lung vasculitis.
Nasser M; Cottin V
Curr Opin Pulm Med; 2020 Sep; 26(5):496-506. PubMed ID: 32740376
[TBL] [Abstract][Full Text] [Related]
38. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
Harris C; Marin J; Beaulieu MC
BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
[TBL] [Abstract][Full Text] [Related]
39. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
40. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
